Literature DB >> 15114591

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma.

Maria Monne1, Giovanna Piras, Angelo Palmas, Luigi Arru, Marco Murineddu, Giancarlo Latte, Annalisa Noli, Attilio Gabbas.   

Abstract

The CTLA-4 molecule plays an important role in immune regulation by downregulating activation of T cells. Polymorphisms in the CTLA-4 gene have been shown to be associated to a number of autoimmune diseases including blood disorders. In this study, the intragenic polymorphisms of the CTLA-4 gene at position -318*C/T, +49*A/G, and the dinucleotide (AT)(n) repeat polymorphism in exon 3 were analyzed in patients with non-Hodgkin's lymphoma. Genotype and haplotype analysis showed that the exon 1+49*AA genotype was over-represented among patients with NHL (P = 0.002), whereas no difference was observed for the -318*C/T promoter and the (AT)(n) polymorphisms (P > 0.05). The data obtained indicate that the CTLA-4+49A/G polymorphism may have a role in genetic susceptibility to NHL. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15114591     DOI: 10.1002/ajh.20045

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  23 in total

Review 1.  Autoimmune effector memory T cells: the bad and the good.

Authors:  Priyadharshini Devarajan; Zhibin Chen
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

2.  Cytotoxic T lymphocyte-associated antigen-4 +49A>G polymorphism and the risk of non-small cell lung cancer in a Chinese population.

Authors:  Hui-Ning Liu; Jian-Ling Su; Shao-Hui Zhou; Li-Jun Liu; Peng Qie
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Cytotoxic T lymphocyte antigen 4 (CTLA4) gene polymorphism with bladder cancer risk in North Indian population.

Authors:  Praveen Kumar Jaiswal; Vibha Singh; Rama Devi Mittal
Journal:  Mol Biol Rep       Date:  2014-01-04       Impact factor: 2.316

4.  CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.

Authors:  Kavita V Shah; Andy J Chien; Cassian Yee; Randall T Moon
Journal:  J Invest Dermatol       Date:  2008-06-19       Impact factor: 8.551

5.  Analysis of single nucleotide polymorphisms in the FAS and CTLA-4 genes of peripheral T-cell lymphomas.

Authors:  Irina Bonzheim; Eva Geissinger; Wen-Yu Chuang; Sabine Roth; Philipp Ströbel; Alexander Marx; Peter Reimer; Martin Wilhelm; Bernhard Puppe; Andreas Rosenwald; Hans Konrad Müller-Hermelink; Thomas Rüdiger
Journal:  J Hematop       Date:  2008-04-24       Impact factor: 0.196

6.  Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma.

Authors:  Anne J Novak; Susan L Slager; Zachary S Fredericksen; Alice H Wang; Michelle M Manske; Steven Ziesmer; Mark Liebow; William R Macon; Stacey R Dillon; Thomas E Witzig; James R Cerhan; Stephen M Ansell
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

7.  CTLA-4 +49A>G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese.

Authors:  Peng Qi; Can-ping Ruan; Hao Wang; Fei-guo Zhou; Xin-yun Xu; Xing Gu; Yun-peng Zhao; Tong-hai Dou; Chun-fang Gao
Journal:  Int J Colorectal Dis       Date:  2009-09-29       Impact factor: 2.571

8.  Associations between CTLA-4 +49 A/G (rs231775) polymorphism and cancer risk: a meta-analysis based on 52 case-control studies.

Authors:  Lu Wang; Zhiwei Jiang; Hao Qiu; Weifeng Tang; Tanghai Duan; Lixin Wang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 9.  Antibody-based immunotherapy for malignant glioma.

Authors:  Patrick C Gedeon; Katherine A Riccione; Peter E Fecci; John H Sampson
Journal:  Semin Oncol       Date:  2014-06-12       Impact factor: 4.929

10.  Potential function of CTLA-4 in the tumourigenic capacity of melanoma stem cells.

Authors:  Bingyu Zhang; Jianzhong Dang; Diandian Ba; Cencen Wang; Juan Han; Fang Zheng
Journal:  Oncol Lett       Date:  2018-08-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.